The present disclosure provides surface functionalized affinity membranes. The surface functionalized affinity membranes can provide increased binding capacity through improved coupling chemistries, ligand densities, spacer arm types, and spacer arm lengths. Methods of preparing the surface functionalized affinity membranes and methods of using the surface functionalized affinity membranes to isolate targets of interest, including nucleic acid molecules and proteins, from a sample are also provided.

The invention relates to the isolation or extraction of exosomes.

Herein is reported the use of an immobilized non-covalent complex of a neonatal Fc receptor (FcRn) and beta-2-microglobulin (b2m) as affinity chromatography ligand in general and, for example, for the determination of the in vivo half-live of an antibody by determining the ratio of the retention times of the antibody and a reference antibody.

Metal organic resins, composite materials composed of the metal organic resins, and anion exchange columns packed with the composite materials are provided. Also provided are methods of using the composite materials to remove metal anions from a sample, methods of using the metal organic resins as fluorescence sensors for detecting metal anions in a sample, and methods of making the metal organic resins and the composite materials. The metal organic resins are amine-functionalized metal organic frameworks and their associated counter anions. The composite materials are composed of metal organic resin particles coated with organic polymers, such as alginic acid polymers.

The invention relates to an immunochromatographic device which contains a nitrous acid compound and an organic acid or an organic acid derivative and which is for detecting a detection target in an analyte wherein a sample droplet-receiving member, a labeling substance-holding member, a chromatography medium member and an absorption member are arranged in a manner that a sample develops in this order and wherein a part containing the nitrous acid compound and a part containing the organic acid or the like are at upstream positions from the labeling substance-containing part, and the part containing the nitrous acid compound and the part containing the organic acid or the like are not substantially in contact with each other in the thickness direction.

The present disclosure is directed to affinity chromatography devices including a fibrillated polymer membrane that contains inorganic particles having a spherical shape and a particle size distribution that has a D90/D10 less than or equal to 3. A blend or a combination of spherical inorganic particles may be utilized. A nominal particle size of the spherical inorganic particles is from about 5 microns to about 20 microns. An affinity ligand may be bonded to the spherical inorganic particles and/or to the fibrillated polymer membrane. Also, the affinity chromatography devices have a hydraulic permeability from about 100 (×10.sup.−12 cm.sup.2) to about 500 (×10.sup.−12 cm.sup.2). Additionally, the affinity chromatography devices have a cycling durability of at least 100 cycles without exceeding an pressure of 0.3 MPa. Manifolds containing multiple affinity chromatography devices in a parallel configuration and multiple manifolds in a parallel configuration are also disclosed.

The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.

Provided are immunoglobulin-binding protein variants with increased alkali tolerance, and uses thereof, and more particularly to immunoglobulin-binding protein variants with increased alkali tolerance relative to the wild type due to mutations in amino acids at specific positions in the B3 domain of the immunoglobulin-binding proteins

This invention teaches a targeted apheresis method of treating a pregnant woman with preeclampsia, or who is predisposed to developing preeclampsia, utilizing immobilized binding agents contained within an apheresis device to remove sVEGFR-1 and sVEGFR-2, and one or more other harmful factors associated with preeclampsia selected from a list that includes: sEndoglin, Endothelin-1, TNF, IL-1, IL-6, IL-12, IL-18, digitalis-like factor, ouabain-like factor, marinobufagenin, .marinobufotoxenin, and telocinobufagin. The binding agents used are antibodies or aptamers or binding peptides. Reducing the concentration of sVEGFR-1, sVEGFR-2 and other harmful factors in the pregnant woman's blood using targeted apheresis will alleviate or delay the symptoms of preeclampsia, and thus postpone premature delivery of the baby so that the baby is born at term or as close to term as possible.

The invention concerns biocompatible polymer systems comprising at least one polymer with a plurality of pores, said polymer comprising either polyol or zwitterionic groups designed to adsorb endotoxins and other inflammatory mediator molecules. The inventions are in the field of porous polymeric sorbents, also in the field of broadly reducing endotoxins in blood and blood products that can cause endotoxemia, additionally, in the field of broadly removing endotoxins by perfusion or hemoperfusion.